메뉴 건너뛰기




Volumn 7, Issue 2, 2012, Pages 159-166

Living life without B cells: Is repeated B-cell depletion a safe and effective long-term treatment plan for rheumatoid arthritis?

Author keywords

adverse effects; anti CD20; B cells; rheumatoid arthritis; rituximab; treatment efficacy

Indexed keywords

CHIMERIC ANTIBODY; GLUCOCORTICOID; PLACEBO; RITUXIMAB;

EID: 84859398755     PISSN: 17584272     EISSN: 17584280     Source Type: Journal    
DOI: 10.2217/ijr.12.7     Document Type: Review
Times cited : (33)

References (46)
  • 1
    • 76849086881 scopus 로고    scopus 로고
    • Targeting B cells in immune-mediated infammatory disease: A comprehensive review of mechanisms of action and identifcation of biomarkers
    • Dorner T, Kinnman N, Tak PP. Targeting B cells in immune-mediated infammatory disease: a comprehensive review of mechanisms of action and identifcation of biomarkers. Pharmacol. Ther. 125(3), 464-475 (2010).
    • (2010) Pharmacol. Ther. , vol.125 , Issue.3 , pp. 464-475
    • Dorner, T.1    Kinnman, N.2    Tak, P.P.3
  • 3
    • 38149065192 scopus 로고    scopus 로고
    • Updates from B cell trials: Effcacy
    • Cohen SB. Updates from B cell trials: effcacy. J. Rheumatol. Suppl. 77, 12-17 (2006).
    • (2006) J. Rheumatol. Suppl. , vol.77 , pp. 12-17
    • Cohen, S.B.1
  • 4
    • 77953715791 scopus 로고    scopus 로고
    • Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate
    • Cohen SB, Keystone E, Genovese MC et al. Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate. Ann. Rheum. Dis. 69(6), 1158-1161 (2010).
    • (2010) Ann. Rheum. Dis. , vol.69 , Issue.6 , pp. 1158-1161
    • Cohen, S.B.1    Keystone, E.2    Genovese, M.C.3
  • 6
    • 82755176118 scopus 로고    scopus 로고
    • Safety and effectiveness of rituximab in patients with rheumatoid arthritis following an inadequate response to 1 prior tumor necrosis factor inhibitor: The RESET trial
    • Haraoui B, Bokarewa M, Kallmeyer I, Bykerk V P. Safety and effectiveness of rituximab in patients with rheumatoid arthritis following an inadequate response to 1 prior tumor necrosis factor inhibitor: the RESET trial. J. Rheumatol. 38(12), 2548-2556 (2011).
    • (2011) J. Rheumatol. , vol.38 , Issue.12 , pp. 2548-2556
    • Haraoui, B.1    Bokarewa, M.2    Kallmeyer, I.3    Bykerk, V.P.4
  • 7
    • 34548249142 scopus 로고    scopus 로고
    • Repeated B-cell depletion in clinical practice [5]
    • DOI 10.1093/rheumatology/kem164
    • Edwards JC, Cambridge G, Leandro MJ. Repeated B-cell depletion in clinical practice. Rheumatology (Oxf.) 46(9), 1509 (2007). (Pubitemid 47321579)
    • (2007) Rheumatology , vol.46 , Issue.9 , pp. 1509
    • Edwards, J.C.W.1    Cambridge, G.2    Leandro, M.J.3
  • 8
    • 27544508559 scopus 로고    scopus 로고
    • Tolerability and safety of rituximab (MabThera)
    • Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat. Rev. 31(6), 456-473 (2005).
    • (2005) Cancer Treat. Rev. , vol.31 , Issue.6 , pp. 456-473
    • Kimby, E.1
  • 9
    • 45349102781 scopus 로고    scopus 로고
    • Anti-CD20 therapy in patients with rheumatoid arthritis: Predictors of response and b cell subset regeneration after repeated treatment
    • DOI 10.1002/art.23473
    • Roll P, Dorner T, Tony HP. Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment. Arthritis Rheum. 58(6), 1566-1575 (2008). (Pubitemid 351847509)
    • (2008) Arthritis and Rheumatism , vol.58 , Issue.6 , pp. 1566-1575
    • Roll, P.1    Dorner, T.2    Tony, H.-P.3
  • 10
    • 82555190963 scopus 로고    scopus 로고
    • Effect of rituximab on human in vivo antibody immune responses
    • Pescovitz MD, Torgerson TR, Ochs HD et al. Effect of rituximab on human in vivo antibody immune responses. J. Allergy Clin. Immunol. 128(6), 1295-1302 (2011).
    • (2011) J. Allergy Clin. Immunol. , vol.128 , Issue.6 , pp. 1295-1302
    • Pescovitz, M.D.1    Torgerson, T.R.2    Ochs, H.D.3
  • 11
    • 79958071035 scopus 로고    scopus 로고
    • The anti-CD20 antibody rituximab reduces the Th17 cell response
    • van de Veerdonk FL, Lauwerys B, Marijnissen RJ et al. The anti-CD20 antibody rituximab reduces the Th17 cell response. Arthritis Rheum. 63(6), 1507-1516 (2011).
    • (2011) Arthritis Rheum. , vol.63 , Issue.6 , pp. 1507-1516
    • Van De Veerdonk, F.L.1    Lauwerys, B.2    Marijnissen, R.J.3
  • 12
    • 68849127971 scopus 로고    scopus 로고
    • Synovial tissue sublining CD68 expression is a biomarker of therapeutic response in rheumatoid arthritis clinical trials: Consistency across centers
    • Bresnihan B, Pontifex E, Thurlings RM et al. Synovial tissue sublining CD68 expression is a biomarker of therapeutic response in rheumatoid arthritis clinical trials: consistency across centers. J. Rheumatol. 36(8), 1800-1802 (2009).
    • (2009) J. Rheumatol. , vol.36 , Issue.8 , pp. 1800-1802
    • Bresnihan, B.1    Pontifex, E.2    Thurlings, R.M.3
  • 14
    • 79959832697 scopus 로고    scopus 로고
    • Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: Results of a Phase 2, randomized, placebo-controlled, dose-fnding trial
    • Genovese MC, Kinnman N, de La Bourdonnaye G, Pena Rossi C, Tak PP. Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a Phase 2, randomized, placebo-controlled, dose-fnding trial. Arthritis Rheum. 63(7), 1793-1803 (2011).
    • (2011) Arthritis Rheum. , vol.63 , Issue.7 , pp. 1793-1803
    • Genovese, M.C.1    Kinnman, N.2    De La Bourdonnaye, G.3    Pena Rossi, C.4    Tak, P.P.5
  • 16
    • 73249114021 scopus 로고    scopus 로고
    • Suppressive functions of activated B cells in autoimmune diseases reveal the dual roles of Toll-like receptors in immunity Immunol
    • Lampropoulou V, Calderon-Gomez E, Roch T et al. Suppressive functions of activated B cells in autoimmune diseases reveal the dual roles of Toll-like receptors in immunity Immunol. Rev. 233(1), 146-161 (2010).
    • (2010) Rev. , vol.233 , Issue.1 , pp. 146-161
    • Lampropoulou, V.1    Calderon-Gomez, E.2    Roch, T.3
  • 17
    • 83455169104 scopus 로고    scopus 로고
    • + cells in the peripheral blood of rheumatoid arthritis patients is higher compared to healthy subjects
    • + cells in the peripheral blood of rheumatoid arthritis patients is higher compared to healthy subjects. Arthritis Res. Ther. 13(6), R208 (2011).
    • (2011) Arthritis Res. Ther. , vol.13 , Issue.6
    • Eggleton, P.1    Bremer, E.2    Tarr, J.M.3
  • 20
    • 79955806071 scopus 로고    scopus 로고
    • Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis
    • Buch MH, Smolen JS, Betteridge N et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann. Rheum. Dis. 70(6), 909-920 (2011).
    • (2011) Ann. Rheum. Dis. , vol.70 , Issue.6 , pp. 909-920
    • Buch, M.H.1    Smolen, J.S.2    Betteridge, N.3
  • 21
    • 82355169068 scopus 로고    scopus 로고
    • Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: A retrospective pooled analysis
    • Emery P, Mease PJ, Rubbert-Roth A et al. Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysis. Rheumatology (Oxf.) 50(12), 2223-2232 (2011).
    • (2011) Rheumatology (Oxf.) , vol.50 , Issue.12 , pp. 2223-2232
    • Emery, P.1    Mease, P.J.2    Rubbert-Roth, A.3
  • 22
    • 77951830908 scopus 로고    scopus 로고
    • Effects of early rituximab retreatment in rheumatoid arthritis patients with an inadequate response after the frst cycle: Retrospective arthritis cohort study
    • Bastian H, Zinke S, Egerer K et al. Effects of early rituximab retreatment in rheumatoid arthritis patients with an inadequate response after the frst cycle: retrospective arthritis cohort study. J. Rheumatol. 37(5), 1069-1071 (2010).
    • (2010) J. Rheumatol. , vol.37 , Issue.5 , pp. 1069-1071
    • Bastian, H.1    Zinke, S.2    Egerer, K.3
  • 23
    • 34047142747 scopus 로고    scopus 로고
    • Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs
    • DOI 10.1093/rheumatology/kel393
    • Popa C, Leandro MJ, Cambridge G, Edwards JC. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 years. Rheumatology (Oxf.) 46(4), 626-630 (2007). (Pubitemid 46523308)
    • (2007) Rheumatology , vol.46 , Issue.4 , pp. 626-630
    • Popa, C.1    Leandro, M.J.2    Cambridge, G.3    Edwards, J.C.W.4
  • 24
    • 84857238940 scopus 로고    scopus 로고
    • Biological treatment of rheumatoid arthritis: Towards a more cost-effective re-treatment regimen using rituximab?
    • Boumans MJ, Vos K, Gerlag DM, Tak PP. Biological treatment of rheumatoid arthritis: towards a more cost-effective re-treatment regimen using rituximab? Ann. Rheum. Dis. 71(3), 472-473 (2012).
    • (2012) Ann. Rheum. Dis. , vol.71 , Issue.3 , pp. 472-473
    • Boumans, M.J.1    Vos, K.2    Gerlag, D.M.3    Tak, P.P.4
  • 25
    • 70049108310 scopus 로고    scopus 로고
    • Short-and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis
    • Rehnberg M, Amu S, Tarkowski A, Bokarewa MI, Brisslert M. Short-and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis. Arthritis Res. Ther. 11(4), R123 (2009).
    • (2009) Arthritis Res. Ther. , vol.11 , Issue.4
    • Rehnberg, M.1    Amu, S.2    Tarkowski, A.3    Bokarewa, M.I.4    Brisslert, M.5
  • 26
    • 77953367640 scopus 로고    scopus 로고
    • hi) B cells in infamed lymph nodes are associated with the onset of infammatory-erosive arthritis in TNF-transgenic mice and are targets of anti-CD20 therapy
    • hi) B cells in infamed lymph nodes are associated with the onset of infammatory-erosive arthritis in TNF-transgenic mice and are targets of anti-CD20 therapy. J. Immunol. 184(11), 6142-6150 (2010).
    • (2010) J. Immunol. , vol.184 , Issue.11 , pp. 6142-6150
    • Li, J.1    Kuzin, I.2    Moshkani, S.3
  • 27
    • 77956158598 scopus 로고    scopus 로고
    • Targeting the B cell in rheumatoid arthritis
    • Cohen SB. Targeting the B cell in rheumatoid arthritis. Best Pract. Res. Clin. Rheumatol. 24(4), 553-563 (2010).
    • (2010) Best Pract. Res. Clin. Rheumatol. , vol.24 , Issue.4 , pp. 553-563
    • Cohen, S.B.1
  • 28
    • 70049095511 scopus 로고    scopus 로고
    • Long-term effects of rituximab in rheumatoid arthritis: Clinical, biologic, and pharmacogenetic aspects
    • Quartuccio L, Lombardi S, Fabris M et al. Long-term effects of rituximab in rheumatoid arthritis: clinical, biologic, and pharmacogenetic aspects. Ann. NY Acad. Sci. 1173, 692-700 (2009).
    • (2009) Ann. NY Acad. Sci. , vol.1173 , pp. 692-700
    • Quartuccio, L.1    Lombardi, S.2    Fabris, M.3
  • 29
    • 77949673916 scopus 로고    scopus 로고
    • Long term safety of patients receiving rituximab in rheumatoid arthritis clinical trials
    • van Vollenhoven RF, Emery P, Bingham CO 3rd et al. Long term safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J. Rheumatol. 37(3), 558-567 (2010).
    • (2010) J. Rheumatol. , vol.37 , Issue.3 , pp. 558-567
    • Van Vollenhoven, R.F.1    Emery, P.2    Bingham III, C.O.3
  • 30
    • 33747338728 scopus 로고    scopus 로고
    • Tumor necrosis factor inhibitors for rheumatoid arthritis
    • Scott DL, Kingsley GH. Tumor necrosis factor inhibitors for rheumatoid arthritis. N. Engl. J. Med. 355(7), 704-712 (2006).
    • (2006) N. Engl. J. Med. , vol.355 , Issue.7 , pp. 704-712
    • Scott, D.L.1    Kingsley, G.H.2
  • 31
    • 78650908659 scopus 로고    scopus 로고
    • Does rituximab increase the incidence of infectious complications? A narrative review
    • Kelesidis T, Daikos G, Boumpas D, Tsiodras S. Does rituximab increase the incidence of infectious complications? A narrative review. Int. J. Infect. Dis. 15(1), e2-e16 (2011).
    • (2011) Int. J. Infect. Dis. , vol.15 , Issue.1
    • Kelesidis, T.1    Daikos, G.2    Boumpas, D.3    Tsiodras, S.4
  • 32
    • 77956391149 scopus 로고    scopus 로고
    • Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry
    • Gottenberg JE, Ravaud P, Bardin T et al. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry Arthritis Rheum. 62(9), 2625-2632 (2010).
    • (2010) Arthritis Rheum. , vol.62 , Issue.9 , pp. 2625-2632
    • Gottenberg, J.E.1    Ravaud, P.2    Bardin, T.3
  • 33
    • 77949570681 scopus 로고    scopus 로고
    • Safety of rituximab in rheumatoid arthritis patients with a history of severe or recurrent bacterial infection: Observational study of 30 cases in everyday practice
    • Toussirot E, Pertuiset E, Sordet C et al. Safety of rituximab in rheumatoid arthritis patients with a history of severe or recurrent bacterial infection: observational study of 30 cases in everyday practice. Joint Bone Spine 77(2), 142-145 (2010).
    • (2010) Joint Bone Spine , vol.77 , Issue.2 , pp. 142-145
    • Toussirot, E.1    Pertuiset, E.2    Sordet, C.3
  • 34
    • 79954524343 scopus 로고    scopus 로고
    • Malignancies after rituximab treatment: Just coincidence or more?
    • Aksoy S, Arslan C, Harputluoglu H, Dizdar O, Altundag K. Malignancies after rituximab treatment: just coincidence or more? J. BUON 16(1), 112-115 (2011).
    • (2011) J. BUON , vol.16 , Issue.1 , pp. 112-115
    • Aksoy, S.1    Arslan, C.2    Harputluoglu, H.3    Dizdar, O.4    Altundag, K.5
  • 35
    • 83855160892 scopus 로고    scopus 로고
    • Increased hepatitis C viral load and reactivation of liver disease in HCV RNA-positive patients with onco-haematological disease undergoing chemotherapy
    • Coppola N, Pisaturo M, Guastaferro S et al. Increased hepatitis C viral load and reactivation of liver disease in HCV RNA-positive patients with onco-haematological disease undergoing chemotherapy. Dig. Liver Dis. 44(1), 49-54 (2012).
    • (2012) Dig. Liver Dis. , vol.44 , Issue.1 , pp. 49-54
    • Coppola, N.1    Pisaturo, M.2    Guastaferro, S.3
  • 36
    • 80052777262 scopus 로고    scopus 로고
    • Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis
    • Clifford DB, Ances B, Costello C et al. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch. Neurol. 68(9), 1156-1164 (2011).
    • (2011) Arch. Neurol. , vol.68 , Issue.9 , pp. 1156-1164
    • Clifford, D.B.1    Ances, B.2    Costello, C.3
  • 37
    • 77950337482 scopus 로고    scopus 로고
    • Rituximab-associated infections
    • Gea-Banacloche JC. Rituximab-associated infections. Semin. Hematol. 47(2), 187-198 (2010).
    • (2010) Semin. Hematol. , vol.47 , Issue.2 , pp. 187-198
    • Gea-Banacloche, J.C.1
  • 38
    • 79961111815 scopus 로고    scopus 로고
    • Late-onset neutropenia following rituximab therapy in rheumatic diseases: Association with B lymphocyte depletion and infections
    • Tesfa D, Ajeganova S, Hagglund H et al. Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections. Arthritis Rheum. 63(8), 2209-2214 (2011).
    • (2011) Arthritis Rheum. , vol.63 , Issue.8 , pp. 2209-2214
    • Tesfa, D.1    Ajeganova, S.2    Hagglund, H.3
  • 39
    • 77957275541 scopus 로고    scopus 로고
    • Late-onset neutropenia after rituximab treatment: Case series and comprehensive review of the literature
    • Wolach O, Bairey O, Lahav M. Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature. Med. (Baltimore) 89(5), 308-318 (2010).
    • (2010) Med. (Baltimore) , vol.89 , Issue.5 , pp. 308-318
    • Wolach, O.1    Bairey, O.2    Lahav, M.3
  • 41
    • 69949148371 scopus 로고    scopus 로고
    • Effects of biologics on vascular function and atherosclerosis associated with rheumatoid arthritis
    • Kerekes G, Soltesz P, Der H et al. Effects of biologics on vascular function and atherosclerosis associated with rheumatoid arthritis. Ann. NY Acad. Sci. 1173, 814-821 (2009).
    • (2009) Ann. NY Acad. Sci. , vol.1173 , pp. 814-821
    • Kerekes, G.1    Soltesz Der P, H.2
  • 42
    • 72449136292 scopus 로고    scopus 로고
    • Insights into the heterogeneity of human B cells: Diverse functions, roles in autoimmunity, and use as therapeutic targets
    • doi:10.1007/s12026-009-8096-7 2009 Epub ahead of print
    • Anolik JH, Looney RJ, Lund FE, Randall TD, Sanz I. Insights into the heterogeneity of human B cells: diverse functions, roles in autoimmunity, and use as therapeutic targets. Immunol. Res. doi:10.1007/s12026-009-8096-7 (2009) (Epub ahead of print).
    • Immunol. Res
    • Anolik, J.H.1    Looney, R.J.2    Lund, F.E.3    Randall, T.D.4    Sanz, I.5
  • 43
    • 72449140060 scopus 로고    scopus 로고
    • Novel human transitional B cell populations revealed by B cell depletion therapy
    • Palanichamy A, Barnard J, Zheng B et al. Novel human transitional B cell populations revealed by B cell depletion therapy. J. Immunol. 182(10), 5982-5993 (2009).
    • (2009) J. Immunol. , vol.182 , Issue.10 , pp. 5982-5993
    • Palanichamy, A.1    Barnard, J.2    Zheng, B.3
  • 44
    • 59949089567 scopus 로고    scopus 로고
    • Serum BLyS levels increase after rituximab as initial therapy in patients with follicular Grade 1 non-Hodgkin lymphoma
    • Ansell SM, Novak AJ, Ziesmer S et al. Serum BLyS levels increase after rituximab as initial therapy in patients with follicular Grade 1 non-Hodgkin lymphoma. Am. J. Hematol. 84(2), 71-73 (2009).
    • (2009) Am. J. Hematol. , vol.84 , Issue.2 , pp. 71-73
    • Ansell, S.M.1    Novak, A.J.2    Ziesmer, S.3
  • 45
    • 33947118656 scopus 로고    scopus 로고
    • Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis
    • DOI 10.1016/j.clim.2006.12.006, PII S1521661606009946
    • Sfkakis PP, Souliotis VL, Fragiadaki KG, Moutsopoulos HM, Boletis JN. Theoflopoulos AN. Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis. Clin. Immunol. 123(1), 66-73 (2007). (Pubitemid 46401511)
    • (2007) Clinical Immunology , vol.123 , Issue.1 , pp. 66-73
    • Sfikakis, P.P.1    Souliotis, V.L.2    Fragiadaki, K.G.3    Moutsopoulos, H.M.4    Boletis, J.N.5    Theofilopoulos, A.N.6
  • 46
    • 59249101969 scopus 로고    scopus 로고
    • Protein biochip array technology to monitor rituximab in rheumatoid arthritis
    • Fabre S, Guisset C, Tatem L et al. Protein biochip array technology to monitor rituximab in rheumatoid arthritis. Clin. Exp. Immunol. 155(3), 395-402 (2009).
    • (2009) Clin. Exp. Immunol. , vol.155 , Issue.3 , pp. 395-402
    • Fabre, S.1    Guisset, C.2    Tatem, L.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.